摘要： PBI16 COST ANALYSIS OF TWO TREATMENTS BY INFLIXIMAB (ORIGINATOR AND BIOSIMILAR) FOR PATIENTS WITH RHUMATOÏD ARTHRITIS (RA) OR INFLAMMATORY BOWEL DISEASE (IBD) IN A GROUP OF FRENCH PUBLIC HOSPITALS (UNIHA) RA and IBD remain chronic pathologies with long term treatments like infliximab, a chimeric immunoglobulin targeting tumor necrosis factor-alpha. Methods A Cost Analysis has been performed with 2 cohorts of patients from UniHA hospitals (a French purchasing group of public hospitals), according to the FHI perspective. [Extracted from the article]